With trial starts and a takeout, γδ therapies start coming of age 

A cluster of trial starts, preliminary Phase I data and a consummated build-to-buy deal show γδ T cell-based cancer therapies are gaining momentum, with a fresh batch of data at SITC and ASH. 

The T cell subset, whose stress signal-detecting, HLA-independent TCR makes it a good fit for allogeneic cell therapies, sparked a wave of company creation about six years ago. Among the promising signals were clinical biomarker data showing high levels of tumor-infiltrating γδ T cells were predictive of favorable outcomes across a wide range of solid tumor types...